These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 26470761)

  • 1. Association of Implantable Cardioverter Defibrillator Therapy with All-Cause Mortality-A Systematic Review and Meta-Analysis.
    Qian Z; Zhang Z; Guo J; Wang Y; Hou X; Feng G; Zou J
    Pacing Clin Electrophysiol; 2016 Jan; 39(1):81-8. PubMed ID: 26470761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Inappropriate Shocks and Other Health Outcomes Between Single- and Dual-Chamber Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death: Results From the Cardiovascular Research Network Longitudinal Study of Implantable Cardioverter-Defibrillators.
    Peterson PN; Greenlee RT; Go AS; Magid DJ; Cassidy-Bushrow A; Garcia-Montilla R; Glenn KA; Gurwitz JH; Hammill SC; Hayes J; Kadish A; Reynolds K; Sharma P; Smith DH; Varosy PD; Vidaillet H; Zeng CX; Normand ST; Masoudi FA
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The gender-paradox among patients with implantable cardioverter-defibrillators: a propensity-matched study.
    Bhavnani SP; Pavuluri V; Coleman CI; Guertin D; Yarlagadda RK; Clyne CA; Kluger J
    Pacing Clin Electrophysiol; 2013 Jul; 36(7):878-84. PubMed ID: 23614760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mortality and appropriate and inappropriate therapy in patients with ischaemic heart disease and implanted cardioverter-defibrillators for primary prevention: data from the Danish ICD Register.
    Weeke P; Johansen JB; Jørgensen OD; Nielsen JC; Møller M; Videbæk R; Højgaard MV; Riahi S; Jacobsen PK
    Europace; 2013 Aug; 15(8):1150-7. PubMed ID: 23407630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association between ICD interventions and mortality is independent of their modality: clinical implications.
    Bencardino G; Di Monaco A; Rio T; Frontera A; Santangeli P; Leo M; Pelargonio G; Perna F; Narducci ML; Gabrielli F; Lanza GA; Bellocci F; Rebuzzi A; Crea F
    J Cardiovasc Electrophysiol; 2014 Dec; 25(12):1363-7. PubMed ID: 25066621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Implantable Cardioverter-Defibrillator Interventions on All-Cause Mortality in Heart Failure Patients: A Meta-Analysis.
    Bazoukis G; Tse G; Korantzopoulos P; Liu T; Letsas KP; Stavrakis S; Naka KK
    Cardiol Rev; 2019; 27(3):160-166. PubMed ID: 30052536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical course and prognostic relevance of antitachycardia pacing-terminated ventricular tachyarrhythmias in implantable cardioverter-defibrillator patients.
    Kleemann T; Strauss M; Kouraki K; Zahn R
    Europace; 2015 Jul; 17(7):1068-75. PubMed ID: 25687746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertrophic Cardiomyopathy and Implantable Defibrillators in Sweden: Inappropriate Shocks and Complications Requiring Surgery.
    Magnusson P; Gadler F; Liv P; Mörner S
    J Cardiovasc Electrophysiol; 2015 Oct; 26(10):1088-94. PubMed ID: 26178879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review and meta-analysis of the association between implantable cardioverter-defibrillator shocks and long-term mortality.
    Proietti R; Labos C; Davis M; Thanassoulis G; Santangeli P; Russo V; Di Biase L; Roux JF; Verma A; Natale A; Essebag V
    Can J Cardiol; 2015 Mar; 31(3):270-7. PubMed ID: 25746019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex difference in appropriate shocks but not mortality during long-term follow-up in patients with implantable cardioverter-defibrillators.
    Seegers J; Conen D; Jung K; Bergau L; Dorenkamp M; Lüthje L; Sohns C; Sossalla ST; Fischer TH; Hasenfuss G; Friede T; Zabel M
    Europace; 2016 Aug; 18(8):1194-202. PubMed ID: 26622054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between myocardial substrate, implantable cardioverter defibrillator shocks and mortality in MADIT-CRT.
    Sood N; Ruwald AC; Solomon S; Daubert JP; McNitt S; Polonsky B; Jons C; Clyne CA; Zareba W; Moss AJ
    Eur Heart J; 2014 Jan; 35(2):106-15. PubMed ID: 24179073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT).
    Ruwald AC; Schuger C; Moss AJ; Kutyifa V; Olshansky B; Greenberg H; Cannom DS; Estes NA; Ruwald MH; Huang DT; Klein H; McNitt S; Beck CA; Goldstein R; Brown MW; Kautzner J; Shoda M; Wilber D; Zareba W; Daubert JP
    Circ Arrhythm Electrophysiol; 2014 Oct; 7(5):785-92. PubMed ID: 25136077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of mortality in patients with an implantable cardiac defibrillator: a systematic review and meta-analysis.
    Alba AC; Braga J; Gewarges M; Walter SD; Guyatt GH; Ross HJ
    Can J Cardiol; 2013 Dec; 29(12):1729-40. PubMed ID: 24267811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automated electrocardiographic quantification of myocardial scar in patients undergoing primary prevention implantable cardioverter-defibrillator implantation: Association with mortality and subsequent appropriate and inappropriate therapies.
    Reichlin T; Asatryan B; Vos MA; Willems R; Huikuri HV; Junttila MJ; Schlögl SC; Hnatkova K; Schaer BA; Malik M; Zabel M; Sticherling C;
    Heart Rhythm; 2020 Oct; 17(10):1664-1671. PubMed ID: 32428669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy.
    Brouwer TF; Yilmaz D; Lindeboom R; Buiten MS; Olde Nordkamp LR; Schalij MJ; Wilde AA; van Erven L; Knops RE
    J Am Coll Cardiol; 2016 Nov; 68(19):2047-2055. PubMed ID: 27810043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of implantable cardioverter-defibrillator for secondary prevention in chagas' heart disease.
    Martinelli M; de Siqueira SF; Sternick EB; Rassi A; Costa R; Ramires JA; Kalil Filho R
    Am J Cardiol; 2012 Oct; 110(7):1040-5. PubMed ID: 22727179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Very high rate programming in primary prevention patients with reduced ejection fraction implanted with a defibrillator: Results from a large multicenter controlled study.
    Clementy N; Challal F; Marijon E; Boveda S; Defaye P; Leclercq C; Deharo JC; Sadoul N; Klug D; Piot O; Gras D; Bordachar P; Algalarrondo V; Fauchier L; Babuty D;
    Heart Rhythm; 2017 Feb; 14(2):211-217. PubMed ID: 27989789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of subcutaneous implantable cardioverter-defibrillator therapy in patients with Brugada syndrome.
    Shinohara T; Abe I; Hirota K; Kondo H; Fukui A; Akioka H; Teshima Y; Yufu K; Nakagawa M; Takahashi N
    Heart Vessels; 2021 Feb; 36(2):260-266. PubMed ID: 32833119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between atrial fibrillation-triggered implantable cardioverter-defibrillator (ICD) shocks and inappropriate shocks caused by lead failure: different impact on prognosis in clinical practice.
    Kleemann T; Hochadel M; Strauss M; Skarlos A; Seidl K; Zahn R
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):735-40. PubMed ID: 22313314
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.